+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Uncomplicated Urinary Tract Infection - Market Insight, Epidemiology and Market Forecast - 2030

  • ID: 5357291
  • Report
  • July 2021
  • Region: Global
  • 148 pages
  • DelveInsight

FEATURED COMPANIES

  • GlaxoSmithKline
  • Inmunotek
  • Iterum Therapeutics
  • Janssen Pharmaceuticals
  • MORE
This ‘Uncomplicated Urinary Tract Infection (uUTI) - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Uncomplicated Urinary Tract Infection, historical and forecasted epidemiology as well as the Uncomplicated Urinary Tract Infection market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Uncomplicated Urinary Tract Infection market report provides current treatment practices, emerging drugs, Uncomplicated Urinary Tract Infection market share of the individual therapies, current and forecasted Uncomplicated Urinary Tract Infection market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Uncomplicated Urinary Tract Infection treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030

Uncomplicated Urinary Tract Infection (uUTI): Disease Understanding and Treatment Algorithm

Uncomplicated Urinary Tract Infection Overview

A Urinary Tract Infection (UTI) (also known as a bladder infection) is a common condition that occurs when bacteria migrate into the usually sterile urinary tract and multiply. Urinary Tract Infection is caused by a range of pathogens, but most commonly by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus. A UTI can develop in any part of the urinary tract, including the urethra, bladder, ureters, or kidneys. Urinary tract infections are primarily caused by gram-negative bacteria, but gram-positive pathogens may also be involved.

Urinary Tract Infection is classified into complicated or uncomplicated, depending on the presence or absence of structural abnormality, pregnancy, sex, and renal obstructions. Uncomplicated Urinary Tract Infection typically affects individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities; these infections are differentiated into lower urinary tract infection (cystitis) and upper urinary tract infection (pyelonephritis). Several risk factors are associated with cystitis, including female gender, a prior urinary tract infection, sexual activity, vaginal infection, diabetes, obesity, and genetic susceptibility.

Recurrent Urinary Tract Infection is defined as at least two infections within six months or at least three infections within one year. The recurrence of a urinary tract infection may be relapse (i.e., caused by the same uropathogen) or re-infection (i.e., caused by different uropathogens). Most recurrences are likely re-infection rather than relapse. Recurrent urinary tract infection in women is caused by uropathogens that adhere well to the uroepithelial cells. Recurrent urinary tract infections may occur in women of any age, and there may be a genetic predisposition because some women are more likely to develop subsequent infections after the first episode of Urinary Tract Infection.

Uncomplicated Urinary Tract Infection Diagnosis

Frequent sexual intercourse is one of the biggest urinary tract infection risk factors for younger women. For menopausal women, however, physical changes such as the thinning of vaginal tissue, difficulty fully emptying the bladder, incontinence, and pelvic organ prolapse are the main culprits. In addition, during menopause, the body produces less estrogen, a hormone that, among other functions, helps keep the bacteria levels in the lining of the bladder and urethra healthy.

The gold standard for UTI diagnosis is the urine examination, including quantitative urine culture and its assessment, with appropriate clinical examinations and typical symptom assessment. A negative test for nitrite/leukocytes may be considered to rule out UTI with sufficient certainty in patients with a low pretest probability. The detection of blood, leukocytes, and nitrite independently increases the likelihood of the presence of a UTI. Diagnosis of Uncomplicated UTI includes clinical examination based on a focused history of lower urinary tract symptoms and the absence of vaginal discharge or irritation. Further lab tests to confirm the diagnosis include Urinalysis, Urine microscopy, and Urine culture. Other than this, some imaging and other tests can also be used, such as Cystoscopy and Ureteroscopy.

Uncomplicated Urinary Tract Infection Treatment

UTI is treated with antibiotics and sometimes additional medication for pain relief. Antibiotics are still considered the gold standard of UTI treatments. Antibiotics are the first line of treatment for UTI. Treatment is based upon pathogen identification and the type and degree of clinical illness and the presence or absence of predisposing host factors. In general, the treatment consists of hydration, relief of urinary tract obstruction if present, removal of foreign body or catheter if a feasible and judicious use of antibiotics. The type and duration of antibiotic treatment are dependent on the site of infection (pyelonephritis, cystitis), host factors, and severity of illness. Most antibiotics are highly concentrated in the urine and, therefore, effectively clear bacteria from the urinary tract.

Currently, treatment strategies for Uncomplicated Urinary Tract Infection mainly include antibiotic treatment including the combination drug trimethoprim and sulfamethoxazole, trimethoprim, β-lactams, fluoroquinolones, nitrofurantoin, and fosfomycin tromethamine. While most UTIs are considered simple or uncomplicated, the particulars regarding which antibiotics are prescribed and for how long, depending on factors such as the type of bacteria detected in the urine and current health. If the patient has been treated for a UTI in the past, the doctor may recommend a different antibiotic when the patient gets an infection. This is because some types of bacteria that cause UTI have become resistant to certain antibiotics. Other than treatment, antibiotic therapies can also be used for prophylaxis. The most tested schedule of antibiotic prophylaxis (TMP, TMP-SMX, nitrofurantoin, cephalexin) was daily dosing. However, fosfomycin used prophylactically is dosed every 10 days. Some women stay on continuous or postcoital prophylaxis for years to maintain the benefit without adverse events. However, it should be noted that continuing prophylaxis for years is not evidence-based.

Uncomplicated Urinary Tract Infection Epidemiology

The Uncomplicated Urinary Tract Infection epidemiology division provides insights about the historical and current Uncomplicated Urinary Tract Infection patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2020, the total occurrence-specific cases of Uncomplicated Urinary Tract Infection was observed to be 35.3 million cases in the 7MM which are expected to grow during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Uncomplicated Urinary Tract Infection epidemiology [segmented as Total Occurrence-specific Cases of Uncomplicated Urinary Tract Infection, Total Diagnosed Cases of Uncomplicated Urinary Tract Infection, Total Age-specific Cases of Uncomplicated Urinary Tract Infection, Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection, and Total Treated cases (across lines) of Uncomplicated Urinary Tract Infection] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Uncomplicated Urinary Tract Infection Epidemiology

Estimates show that the highest occurrence-specific cases of Uncomplicated Urinary Tract Infection in the 7MM were in the United States, followed by Japan, Italy, France, the United Kingdom, Germany, and Spain in 2020.
  • In the United States, the total number of occurrence-specific cases of Uncomplicated Urinary Tract Infection was 14.7 million cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.
  • In the year 2020, the total occurrence-specific cases of Uncomplicated Urinary Tract Infection were 13.9 million cases in EU-5 which are expected to grow during the study period, i.e., 2018-2030.
  • In Japan, the total number of occurrence-specific cases of Uncomplicated Urinary Tract Infection was 6.7 million cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.
Uncomplicated Urinary Tract Infection Drug Chapters

The drug chapter segment of the Uncomplicated Urinary Tract Infection report encloses the detailed analysis of Uncomplicated Urinary Tract Infection marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Uncomplicated Urinary Tract Infection clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Uncomplicated Urinary Tract Infection Emerging Drugs

GSK2140944/Gepotidacin (GlaxoSmithKline)

Gepotidacin (GSK2140944), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, is in development to treat uUTI. Gepotidacin is the first in a new class of antibiotics developed at GSK in 2007 with a novel “dual targeting” MOA and oral formulation. Its MOA is distinct from any currently approved antibiotic. Gepotidacin works by selectively interacting with two key bacterial enzymes, DNA gyrase, and topoisomerase IV (type II topoisomerases), responsible for bacterial replication. The novel MOA confers activity against most target pathogens resistant to established antibiotics, including fluoroquinolones. Currently, Gepotidacin (GSK2140944) is in the Phase III stage of development. Previously, this drug had completed a Phase II clinical study. Now, the drug is being studied in two Phase III clinical development trials.

Sulopenem Etzadroxil - Probenecid (Iterum Therapeutics)

Iterum Therapeutics is developing its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against various gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. Sulopenem is an orally bioavailable, broad-spectrum penem β-lactam antibiotic that is being developed to treat infections caused by multi-drug resistant bacteria. It is a parenteral thiopenem with broad-spectrum antibacterial activity against most gram-positive and gram-negative bacteria. Sulopenem is not active against Pseudomonas aeruginosa. In addition, this agent is fairly stable against hydrolysis by various beta-lactamases. Currently, Sulopenem is being investigated in Phase I clinical study after completing a Phase III clinical trial for the treatment of uUTI.

In January 2021, Iterum's oral sulopenem was granted priority review by the US FDA to treat certain patients with uUTI. In May 2021, Iterum Therapeutics announced an update on this issue, stating that the company had participated in a late-cycle meeting with the US FDA. The review of the NDA is ongoing, and the company was informed that the US FDA continues to work toward the PDUFA goal date of July 25, 2021.

Uromune/MV140 (Inmunotek)

Uromune is a glycerinated suspension containing whole cell-inactivated bacteria for sublingual administration. It is administered by spraying over the sublingual area. Uromune is intended to be self-administered by the patient. The active substances contained in Uromune are four whole cell-inactivated bacterial strains: Klebsiella pneumoniae (25%), Escherichia coli (25%), Enterococcus faecalis (25%), and Proteus vulgaris (25%) at a final concentration of 300 FTU/mL equivalent to ~109 Bacteria/mL. MV140 (Uromune) is a polyvalent bacterial preparation (PBP) composed of equal proportions of whole heat-inactivated bacteria producing most RUTI in Europe. MV140 (Uromune) endorses human DCs with the capacity to generate Th1, Th17, and IL-10-producing T cells through mechanisms partially depending on spleen tyrosine kinase (Syk)- and myeloid differentiation primary response gene 88 (MyD88)-mediated signaling pathways.

Currently, Uromune is pre-licensed in the Phase III development stage, available under the named patient programs (e.g., compassionate use) in 26 countries worldwide (such as the UK, New Zealand, Netherlands, Germany, Spain, and many other Western European countries).

Note: Detailed emerging therapies assessment will be provided in the final report.

Uncomplicated Urinary Tract Infection Market Outlook

Urinary Tract Infection is an infection in any part of the urinary system, including kidneys, bladder, ureters, and urethra, which has been categorized into uncomplicated and complicated UTI. Uncomplicated Urinary Tract Infection typically affects individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities. In contrast, complicated UTI is associated with factors that compromise the urinary tract or host defense, including urinary obstruction, immunosuppression, renal failure, renal transplantation, pregnancy, indwelling catheters, or other drainage devices.

Currently, antibiotics are still considered the gold standard of UTI treatments. Antibiotics are usually used to manage UTI because they reduce the duration and severity of symptoms and complications. The antimicrobial agents most commonly used to treat uUTI include the combination drug trimethoprim and sulfamethoxazole, trimethoprim, β-lactams, fluoroquinolones, nitrofurantoin, and fosfomycin tromethamine.

In the United States, the guidelines recommend trimethoprim-sulfamethoxazole for empirical treatment of uUTI unless trimethoprim-sulfamethoxazole resistance in a community exceeds 10% to 20%. The rationale for this 10% to 20% cutoff appears to be related to clinical and economic considerations and concerns about the emergence of fluoroquinolone-resistant bacteria. Several commonly used and commercially available fluoroquinolones are approved for the treatment of uUTI in the United States. These include ciprofloxacin, levofloxacin, gatifloxacin, norfloxacin, and ofloxacin, although the latter 2 are now used less frequently. Other treatment options for UTI include amoxicillin and first-generation cephalosporins (eg, cephalexin), but β-lactams are somewhat less effective than trimethoprim-sulfamethoxazole and are associated with more adverse drug effects.

Despite the high prevalence of bladder infections, currently, there are no effective UTI vaccines available for use in the US. Although several vaccines against UTI in Europe have been available and have been investigated in clinical trials, they have so far had limited success. There are currently four available vaccines with established results from randomized control trials (RCT): Uro−Vaxom, Urovac, ExPEC Vaccine, and Uromune.

At present, recently some developmental activities have been initiated toward the management of uUTI. Treatment opportunity is likely to evolve as some exciting therapies, including vaccines, are heading down the pipeline. At present, some companies have commenced clinical trials that investigate new treatment options. Key players such as GlaxoSmithKline (gepotidacin and GSK3882347), Iterum Therapeutics (sulopenem-etzadroxil), Inmunotek (Uromune), Janssen (a subsidiary of Johnson & Johnson; ExPEC Vaccine), and several others are investigating their candidates for the management of uUTI in the 7MM.

Key Findings

The Uncomplicated Urinary Tract Infection market size in the 7MM is expected to change during the study period 2018-2030. The therapeutic market of Uncomplicated Urinary Tract Infection in the seven major markets is expected to increase during the study period (2018-2030) with a CAGR of 10.8%. According to the estimates, the highest market size of Uncomplicated Urinary Tract Infection is found in the United States followed by Japan.

The United States Market Outlook

The total market size of Uncomplicated Urinary Tract Infection therapies in the United States is expected to increase with a CAGR of 11.6% in the study period (2018-2030).

EU-5 Countries: Market Outlook

The total market size of Uncomplicated Urinary Tract Infection therapies in EU-5 countries is expected to increase with a CAGR of 10.5% in the study period (2018-2030).

Japan Market Outlook

The total market size of Uncomplicated Urinary Tract Infection therapies in Japan is expected to increase with a CAGR of 7.1% in the study period (2018-2030).

Uncomplicated Urinary Tract Infection Pipeline Development Activities

The drugs which are in pipeline include:
1. GSK2140944/Gepotidacin (GlaxoSmithKline)
2. Sulopenem Etzadroxil - Probenecid (Iterum Therapeutics)
3. Uromune/MV140 (Inmunotek)
4. ExPEC Vaccine/ExPEC10V and ExPEC4V (Janssen Pharmaceuticals)
5. GSK3882347 (GlaxoSmithKline/Fimbrion Therapeutics)
Note: Detailed emerging therapies assessment will be provided in the final report.

Analyst Commentary
  • AUA/CUA/SUFU guideline-recommended nitrofurantoin, TMP-SMX, fosfomycin as first-line therapy for the treatment of symptomatic UTIs in women. Primarily because of increasing bacterial resistance to other agents, the use of fosfomycin in the United States is starting to increase in the uUTI. However, the poor bioavailability of oral fosfomycin limits its use in patients who are critically ill.
  • The pipeline of uUTI is not very robust and only a few players are active in this space. GlaxoSmithKline (GSK), Inmunotek, and Iterum Therapeutics are currently evaluating the role of their assets in late-stage clinical trial development.
  • Among the emerging therapies, GlaxoSmithKline (GSK) is evaluating the role of GSK2140944 (Gepotidacin) in late-stage uUTI trial, and results are expected from the ongoing phase III trial by 2022. The drug is targeting the broader pool in uUTI and also the company is evaluating the potential against nitrofurantoin as well.
  • Fluoroquinolones initially have also been tried as first-line therapy however, this class is associated with severe adverse events, such as rate-corrected electrocardiographic QT interval prolongation, tendinitis, and tendon rupture, and seizures. On May 12, 2016, the US FDA advised that serious side effects associated with fluoroquinolone use “generally outweigh the benefits for patients with acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections who have other treatment options”. Given these compelling reasons, nitrofurantoin and TMP-SMX along with fosfomycin should be chosen for outpatient treatment of uncomplicated cystitis. Still, around one-third of the current uUTI market is contributed by fluoroquinolones who are mainly reserved for later lines of treatment.
Access and Reimbursement Scenario in Uncomplicated Urinary Tract Infection Therapies

According to the Infectious Diseases Society of America (IDSA), the three first-line agents available in the United States (i.e., nitrofurantoin, TMP-SMX, fosfomycin) effectively treat UTI but are less likely to produce collateral damage than are second-line agents. In March 2019, the European Commission implemented stringent regulatory conditions regarding the use of fluoroquinolones due to their disabling and potentially long-lasting side effects. This legally binding decision is applicable in all EU countries.

National authorities have been urged to enforce the ruling and to take all appropriate measures to promote the correct use of this class of antibiotics. In uncomplicated cystitis, fluoroquinolone should only be used when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections. A study assessed the relative cost-effectiveness of the four antibiotics recommended in England to treat uUTI in adult women. A cost-effectiveness model in adult women with signs and symptoms of uUTI in primary care in England treated with fosfomycin, nitrofurantoin, pivmecillinam, or trimethoprim.

The French National Authority for Health (HAS) in its HTA decision has appointed an SMR rating of “Important”. This rating was given after confirming the actual benefit of Delprim 300 mg tablet as important in treating acute uncomplicated cystitis in adult women and adolescents. Moreover, ASMR V rating (absence) was also given, because of the absence of data on this efficacy at a dose of 300 mg for 3 days, vis-à-vis clinically relevant comparators. Delprim 300 mg does not improve the ASMR V in treating acute uncomplicated cystitis in adult women and adolescents.

As per the study conducted in France by François et al. (2016), on the costs of community UTI in women over 18 years of age estimated a total cost from the societal perspective of EUR 58 million in 2012, EUR 44 million for direct costs, and EUR 14 million for indirect costs. Half of this cost was supported by the French National Health Insurance, and a half was supported by the patients (before private complementary health insurance participation). Visits represented the largest expense item, followed by sick leave and prescription drugs. Although very expensive, hospitalizations were rare and therefore represented the smallest expense item.

In April 2015, NHS England launched a national program to reduce inappropriate antibiotic prescribing, with incentive funding for hospitals and clinical commissioning groups (CCGs). The payments form part of two schemes that reward excellence and quality improvement: the Commissioning for Quality and Innovation (CQUIN) and the Quality Premium (QP) scheme. Other than this, various Patient Access Programs (PAPs) are also available to reduce the economic burden of the patients. Some of these programs include Bayer Patient Assistance Program for Ciprofloxacin, myAbbVie Assist for Fosfomycin, Proctor and Gamble Pharmaceuticals (P&G) Assistance Program for Nitrofurantoin, etc.

Note: Detailed HTA assessment will be provided in the final report.

KOL-Views

To keep up with current market trends, we take KOLs and SME's opinion working in the Uncomplicated Urinary Tract Infection domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Uncomplicated Urinary Tract Infection market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Uncomplicated Urinary Tract Infection Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Uncomplicated Urinary Tract Infection, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Uncomplicated Urinary Tract Infection epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Uncomplicated Urinary Tract Infection is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Uncomplicated Urinary Tract Infection market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Uncomplicated Urinary Tract Infection market.
Report Highlights
  • In the coming years, the Uncomplicated Urinary Tract Infection market is set to change due to the upcoming therapies with a novel mechanism of action which are under investigation and antibiotic stewardship programs; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Uncomplicated Urinary Tract Infection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Uncomplicated Urinary Tract Infection. The launch of emerging therapies will significantly impact the Uncomplicated Urinary Tract Infection market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Uncomplicated Urinary Tract Infection.
  • The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Uncomplicated Urinary Tract Infection Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Uncomplicated Urinary Tract Infection Pipeline Analysis
  • Uncomplicated Urinary Tract Infection Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Uncomplicated Urinary Tract Infection Report Key Strengths
  • 10 Years Forecast
  • 7MM Coverage
  • Uncomplicated Urinary Tract Infection Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Uncomplicated Urinary Tract Infection Report Assessment
  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions Answered

Market Insights:
  • What was the Uncomplicated Urinary Tract Infection Market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Uncomplicated Urinary Tract Infection total market size as well as market size by therapies across the 7MM during the study period (2018-2030)?
  • What are the key findings of the market across the 7MM and which country will have the largest Uncomplicated Urinary Tract Infection market size during the study period (2018-2030)?
  • At what CAGR, the Uncomplicated Urinary Tract Infection market is expected to grow in the 7MM during the study period (2018-2030)?
  • What would be the Uncomplicated Urinary Tract Infection market outlook across the 7MM during the study period (2018-2030)?
  • What would be the Uncomplicated Urinary Tract Infection market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
  • Uncomplicated Urinary Tract Infection patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration, and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Uncomplicated Urinary Tract Infection market?
Epidemiology Insights:
  • What are the disease risks, burdens, and unmet needs of the Uncomplicated Urinary Tract Infection?
  • What is the historical Uncomplicated Urinary Tract Infection patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What would be the forecasted patient pool of Uncomplicated Urinary Tract Infection in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Uncomplicated Urinary Tract Infection?
  • Out of all the 7MM countries, which country would have the highest occurrence-specific population of Uncomplicated Urinary Tract Infection during the study period (2018-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2018-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Uncomplicated Urinary Tract Infection?
Current Treatment Scenario and Emerging Therapies:
  • What are the current options for the treatment of Uncomplicated Urinary Tract Infection?
  • What are the current treatment guidelines for the treatment of Uncomplicated Urinary Tract Infection in the US, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Uncomplicated Urinary Tract Infection?
  • How many therapies are developed by each company for the treatment of Uncomplicated Urinary Tract Infection?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Uncomplicated Urinary Tract Infection?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Uncomplicated Urinary Tract Infection therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Uncomplicated Urinary Tract Infection and their status?
  • What are the key designations that have been granted for the emerging therapies for Uncomplicated Urinary Tract Infection?
  • What is the global historical and forecasted market of Uncomplicated Urinary Tract Infection?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Uncomplicated Urinary Tract Infection market.
  • To understand the future market competition in the Uncomplicated Urinary Tract Infection market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Uncomplicated Urinary Tract Infection in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Uncomplicated Urinary Tract Infection market.
  • To understand the future market competition in the Uncomplicated Urinary Tract Infection market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • GlaxoSmithKline
  • Inmunotek
  • Iterum Therapeutics
  • Janssen Pharmaceuticals
  • MORE
1. Key Insights

2. Report Introduction

3. Uncomplicated Urinary Tract Infection Market Overview at a Glance
3.1. Market Share (%) Distribution of Uncomplicated Urinary Tract Infection in 2018
3.2. Market Share (%) Distribution of Uncomplicated Urinary Tract Infection in 2030

4. Executive Summary of Uncomplicated Urinary Tract Infection (uUTI)
4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview
6.1. Introduction
6.2. Types of UTI
6.3. Signs and Symptoms of Uncomplicated UTI
6.4. Risk Factors and Causes of Uncomplicated UTI
6.5. Pathogenesis of UTI
6.6. Complications of UTI

7. Diagnosis of Uncomplicated UTI
7.1. Diagnostic algorithm
7.2. Clinical Examination
7.3. Lab Tests
7.4. Imaging and other tests
7.4.1. Cystoscopy
7.4.2. Ureteroscopy
7.5. Differential diagnosis

8. Prevention of UTI

9. Diagnostic Guidelines
9.1. European Association of Urology (EAU) Urological Infections Diagnostic Guidelines
9.2. American Urological Association (AUA) Guidelines
9.3. Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)

10. Current Treatment Practices of Uncomplicated UTI
10.1. Treatment Algorithm
10.2. Antibiotic therapy
10.2.1. Uncomplicated cystitis
10.2.2. Uncomplicated pyelonephritis
10.2.3. Recurrent UTI
10.3. Antibiotic prophylaxis

11. Treatment Guidelines
11.1. American Urological Association (AUA) Guidelines
11.2. European Association of Urology (EAU) Urological Infections Treatment Guidelines
11.3. Comparison of AUA/CUA/SUFU and EAU Guidelines
11.4. National Institute for Health and Care Excellence (NICE) Guidelines
11.5. Infectious Diseases Society of America (IDSA), in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) Guidelines
11.6. Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)
11.7. NICE - Antimicrobial prescribing strategy for lower UTI (also called cystitis)

12. Epidemiology and Patient Population
12.1. Key Findings
12.2. Epidemiology of Uncomplicated Urinary Tract Infection (uUTI)
12.3. Epidemiology Scenario
12.3.1. Total Occurrence-specific Cases of Uncomplicated Urinary Tract Infection
12.3.2. Total Diagnosed Cases of Uncomplicated Urinary Tract Infection
12.3.3. Total Age-specific Cases of Uncomplicated Urinary Tract Infection
12.3.4. Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection
12.3.5. Total Treated Cases (across lines) of Uncomplicated Urinary Tract Infection

13. Patient Journey

14. Key Endpoints in Uncomplicated UTI Clinical Trials

15. Emerging Therapies
15.1. GSK2140944 (Gepotidacin): GlaxoSmithKline
15.1.1. Product Description
15.1.2. Other Developmental Activities
15.1.3. Clinical Development
15.1.4. Safety and Efficacy
15.2. Sulopenem Etzadroxil - Probenecid: Iterum Therapeutics
15.2.1. Product Description
15.2.2. Other Developmental Activities
15.2.3. Clinical Development
15.2.4. Safety and Efficacy
15.3. Uromune (MV140): Inmunotek
15.3.1. Product Description
15.3.2. Other Developmental Activities
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.4. ExPEC Vaccine (ExPEC10V and ExPEC4V): Janssen Pharmaceuticals
15.4.1. Product Description
15.4.2. Other Developmental Activities
15.4.3. Clinical Development
15.5. GSK3882347: GlaxoSmithKline/Fimbrion Therapeutics
15.5.1. Product Description
15.5.2. Other Developmental Activities
15.5.3. Clinical Development

16. Uncomplicated Urinary Tract Infection: 7 Major Market Analysis
16.1. Key Findings
16.2. Market Outlook
16.3. Market Size of Uncomplicated Urinary Tract Infection
16.3.1. Total Market Size of Uncomplicated Urinary Tract Infection
16.3.2. Market Size of Uncomplicated Urinary Tract Infection by Therapies

17. Market Access and Reimbursement
17.1. Key HTA decisions for Uncomplicated UTI
17.2. Reimbursement
17.3. Patient Access Programs

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix
22.1. Bibliography
22.2. Report Methodology

23. Publisher Capabilities

24. Disclaimer

25. About the Publisher

List of Tables
Table 1: Summary of uUTI Market and Epidemiology (2018-2030)
Table 2: Key classifications of UTI
Table 3: Cut-off values (colony forming units [CFU]/mL) for the diagnosis of UTI
Table 4: Diagnostic recommendations for Uncomplicated cystitis
Table 5: Diagnostic recommendations for Recurrent UTI
Table 6: Diagnostic recommendations for Uncomplicated pyelonephritis
Table 7: Diagnostic recommendations for recurrent UTI (rUTI)
Table 8: Suggested regimens for antimicrobial therapy in uncomplicated cystitis
Table 9: Suggested regimens for empirical oral antimicrobial therapy in uncomplicated pyelonephritis
Table 10: Suggested regimens for empirical parenteral antimicrobial therapy in uncomplicated
Table 11: Commonly used vaginal estrogen therapy
Table 12: Antibiotic prophylaxis dosing
Table 13: Treatment recommendations for recurrent UTI (rUTI)
Table 14: Treatment recommendations for Uncomplicated cystitis
Table 15: Treatment recommendations for Recurrent UTI
Table 16: Treatment recommendations for Uncomplicated pyelonephritis
Table 17: Treatment recommendations for Uncomplicated pyelonephritis
Table 18: Difference between AUA/CUA/SUFU and EAU Guidelines
Table 19: Total Occurrence-specific Cases of Uncomplicated Urinary Tract Infection (in Thousands) (2018-2030)
Table 20: Total Diagnosed Cases of Uncomplicated Urinary Tract Infection (in Thousands) (2018-2030)
Table 21: Total Age-specific Cases of Uncomplicated Urinary Tract Infection (in Thousands) (2018-2030)
Table 22: Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection (in Thousands) (2018-2030)
Table 23: Total Treated Cases of Uncomplicated Urinary Tract Infection (in Thousands) (2018-2030)
Table 24: GSK2140944 (Gepotidacin), Clinical Trial Description, 2021
Table 25: Sulopenem Etzadroxil - Probenecid, Clinical Trial Description, 2021
Table 26: Uromune (MV140), Clinical Trial Description, 2021
Table 27: ExPEC Vaccine (ExPEC10V and ExPEC4V), Clinical Trial Description, 2021
Table 28: GSK3882347, Clinical Trial Description, 2021
Table 29: 7MM Market Size of Uncomplicated Urinary Tract Infection in USD Million (2018-2030)
Table 30: 7MM Market Size of Uncomplicated Urinary Tract Infection by Therapies in USD Million (2018-2030)
Table 31: Key HTA Decisions

List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Symptoms of Uncomplicated UTI
Figure 3: Risk factors of UTI
Figure 4: Pathogenesis of UTI
Figure 5: Diagnostic algorithm for UTI
Figure 6: Treatment algorithm
Figure 7: Antimicrobial prescribing strategy
Figure 8: Total Occurrence-specific Cases of Uncomplicated Urinary Tract Infection in the 7MM (2018-2030)
Figure 9: Total Diagnosed Cases of Uncomplicated Urinary Tract Infection in the 7MM (2018-2030)
Figure 10: Total Age-specific Cases of Uncomplicated Urinary Tract Infection in the 7MM (2018-2030)
Figure 11: Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection in the 7MM (2018-2030)
Figure 12: Total Treated Cases (across the line) of Uncomplicated Urinary Tract Infection in the 7MM (2018-2030)
Figure 13: Mechanism Targeting the Bacterial Adhesin FimH
Figure 14: Market Size of Uncomplicated Urinary Tract Infection in the 7MM, USD Million (2018-2030)
Figure 15: 7MM Market Size of Uncomplicated Urinary Tract Infection by Therapies in USD Million (2018-2030)
Note: Product cover images may vary from those shown
GlaxoSmithKline
Iterum Therapeutics
Inmunotek
Janssen Pharmaceuticals
GlaxoSmithKline/Fimbrion Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll